“Highly complementary pipeline with approximately 10 clinical readouts expected over the next 18 months (Recursion alone expects 7 clinical trial readouts in that period).”

Several guided readouts did arrive (REC-994 in CCM in September 2024, REC-2282 in NF2 in Q4 2024, REC-4881 FAP data in May and December 2025), but the combined company fell short of ~10: in May 2025 Recursion terminated REC-994, REC-2282 and REC-3964 and cut other programs, the REC-4881 LILAC cancer trial was deprioritised and later terminated without a readout, and the REC-3964 C. difficile readout never occurred.